126 related articles for article (PubMed ID: 6511237)
1. Phase I evaluation of AT-125 single dose every three weeks.
Taylor S; Belt RJ; Joseph U; Haas CD; Hoogstraten B
Invest New Drugs; 1984; 2(3):311-4. PubMed ID: 6511237
[TBL] [Abstract][Full Text] [Related]
2. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study.
Maroun JA; Fields AL; Pater JL; Stewart DJ; Cripps C; Eisenhauer E
Cancer Treat Rep; 1984 Sep; 68(9):1121-3. PubMed ID: 6478451
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion.
Earhart RH; Koeller JM; Davis TE; Borden EC; McGovren JP; Davis HL; Tormey DC
Cancer Treat Rep; 1983; 67(7-8):683-92. PubMed ID: 6871883
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of continuous drug infusions in advanced ovarian carcinoma: acivicin versus vinblastine.
Earhart RH; Khandekar JD; Faraggi D; Schinella RA; Davis TE
Invest New Drugs; 1989 Jul; 7(2-3):255-60. PubMed ID: 2793383
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. A National Cancer Institute of Canada Clinical Trials Group Study.
Eisenhauer EA; Maroun JA; Fields AL; Walde PL
Invest New Drugs; 1987 Dec; 5(4):375-8. PubMed ID: 3436743
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of acivicin in patients with advanced colorectal carcinoma.
Adolphson CC; Ajani JA; Stroehlein JR; Barlogie B; Bodey GP; Korinek J; Bedikian AY
Am J Clin Oncol; 1986 Jun; 9(3):189-91. PubMed ID: 3728371
[TBL] [Abstract][Full Text] [Related]
9. Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors.
Verweij J; van der Burg ME; van Putten WL; Henzen-Logmans SC; Salewski E; Kraemer HP; Stoter G
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):627-32. PubMed ID: 2714339
[TBL] [Abstract][Full Text] [Related]
10. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
Bhargava P; Marshall JL; Rizvi N; Dahut W; Yoe J; Figuera M; Phipps K; Ong VS; Kato A; Hawkins MJ
Clin Cancer Res; 1999 Aug; 5(8):1989-95. PubMed ID: 10473076
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacological study of acivicin by 24-hour continuous infusion.
Weiss GR; McGovren JP; Schade D; Kufe DW
Cancer Res; 1982 Sep; 42(9):3892-5. PubMed ID: 7105049
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of aclacinomycin A administered on a five-consecutive-day schedule.
Woolley PV; Ayoob MJ; Levenson SM; Smith FP
J Clin Pharmacol; 1982; 22(8-9):359-65. PubMed ID: 6957420
[TBL] [Abstract][Full Text] [Related]
13. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule.
Casper ES; Gralla RJ; Young CW
Cancer Res; 1981 Jun; 41(6):2417-20. PubMed ID: 6940656
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of pentamethylmelamine.
Ajani JA; Cabanillas FF; Bodey GP
Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
[TBL] [Abstract][Full Text] [Related]
15. [Phase I and pharmacokinetic study of SM-5887 by 5-day schedule].
Inoue K; Matsumura A; Horikoshi N; Aiba K; Mukaiyama T; Matsumura T; Ogihara A; Sumida T; Ogawa M
Gan To Kagaku Ryoho; 1992 Apr; 19(4):477-82. PubMed ID: 1558397
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
Brown TD; Ettinger DS; Donehower RC
J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770
[TBL] [Abstract][Full Text] [Related]
17. Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture.
Williams MG; Earhart RH; Bailey H; McGovren JP
Cancer Res; 1990 Sep; 50(17):5475-80. PubMed ID: 2386952
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of acivicin in non-small cell lung cancer: a National Cancer Institute of Canada Study.
Maroun JA; Maksymiuk A; Eisenhauer E; Stewart DJ; Young V; Pater J
Cancer Treat Rep; 1986 Nov; 70(11):1327-8. PubMed ID: 3021326
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of acivicin in lung cancer: a Southeastern Cancer Study Group Trial.
Kramer BS; Birch R; Greco A; Prestridge K; Johnson R
Cancer Treat Rep; 1986 Aug; 70(8):1031-2. PubMed ID: 3524833
[No Abstract] [Full Text] [Related]
20. Phase I-II trial of acivicin in adult acute leukemia.
Powell BL; Craig JB; Capizzi RL; Richards F
Invest New Drugs; 1988 Apr; 6(1):41-4. PubMed ID: 3165971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
